NUDE RAT MODELS FOR HUMAN TUMOR-METASTASIS TO CNS - PROCEDURES FOR INTRACAROTID DELIVERY OF CANCER-CELLS AND DRUGS

Citation
At. Myklebust et al., NUDE RAT MODELS FOR HUMAN TUMOR-METASTASIS TO CNS - PROCEDURES FOR INTRACAROTID DELIVERY OF CANCER-CELLS AND DRUGS, Journal of neuro-oncology, 21(3), 1994, pp. 215-224
Citations number
34
Categorie Soggetti
Neurosciences,Oncology
Journal title
ISSN journal
0167594X
Volume
21
Issue
3
Year of publication
1994
Pages
215 - 224
Database
ISI
SICI code
0167-594X(1994)21:3<215:NRMFHT>2.0.ZU;2-T
Abstract
Models for hematogenous spread of human cancer to the central nervous system (CNS) were established by injecting human tumor cells into the internal carotid artery of nude rats. With 4 out of 10 cell lines, bel onging to four different tumor types, metastases developed in all inje cted animals. Tumor growth manifested clinically as neurological sympt oms which appeared after a median latency ranging from 19-87 days for the different tumors. The H-146 and DMS-273 small cell lung cancers an d the LOX melanoma almost exclusively gave meningeal tumors, whereas w ith FEMX-I melanoma cells bone metastases in the skull dominated. For these tumor types a correlation was found between the capacity for exp erimental metastasis formation and the s.c. tumorigenicity. In agreeme nt with clinical experience, none of the 2 sarcoma and 2 glioblastoma lines gave CNS metastases. With a modified microsurgical technique, al lowing for repeated ipsilateral intracarotid injections, we analyzed t he drug concentrations obtained in tumor and surrounding brain tissue after i.v. treatment with doxorubicin. The concentration in the LOX tu mor reached therapeutic levels and was approximately 100 x higher than in normal brain tissue, both with and without intraarterial pretreatm ent with arabinose. In the same model, the tissue concentrations of 9. 2.27-abrin immunotoxin 10 min after intracarotid injection were examin ed. Although the levels were low, a tumor to brain concentration ratio of up to 9 was achieved. The data demonstrate that clinically relevan t tumor models can be established with the techniques described, and t hese models may successfully be used to evaluate the pharmacokinetics and effect of intravenous or intraarterial therapy.